The Use of Optical Genome Mapping for the Detection of Tyrosine Kinase Gene Fusions in Myeloid/Lymphoid Neoplasms
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70640 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Justine Vanhevel und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for the Cytogenetic and Molecular Diagnosis of Hematological Malignancies, Centre for Human Genetics, University Hospitals, Leuven, Belgiu…. Hauptthemen laut MEDLINE: Oncogene Proteins, Fusion, Protein-Tyrosine Kinases, Chromosome Mapping, Gene Fusion. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research supported by the Funds Catharina Weekers, Raymond Wuyts, Arlette Lemaître, Yvette Gembauve and Cambier-Sandra, managed by the King Baudouin Foundation.
Abstract (Originalsprache)
Myeloid/Lymphoid Neoplasms with eosinophilia and involvement of Tyrosine Kinase gene fusions (MLN‐TK) is a WHO disease category including a diverse group of malignancies characterised by recurrent genomic rearrangements of tyrosine kinase (TK) genes such as PDGFRA , PDGFRB , FGFR1 , JAK2 , ETV6 and FLT3 . Identification of these TK rearrangements is important for the accurate diagnosis of MLN‐TK and allows targeted therapy with TK inhibitors. In this study, we validated the use of optical genome mapping (OGM) retrospectively by analysing 11 samples from 10 cases with suspected or known TK rearrangements, previously analysed by current standard of care (SOC) methodologies, i.e., chromosome banding analysis (CBA), FISH and/or PCR‐based techniques. In six abnormal cases, OGM was able to detect the rearrangements previously determined by SOC methods. Furthermore, OGM identified the fusion partner in the JAK2 ‐ and PDGFRB ‐rearranged cases and elucidated the mechanism underlying the BCR::FGFR1 and ETV6::SYK rearrangement. In two cases with a normal karyotype, OGM detected two cryptic FIP1L1::PDGFRA and TNIP1::PDGFRB rearrangements. In the two remaining cases, no abnormalities were detected either by OGM or SOC methods. We demonstrate that OGM is a valid technique for the diagnostic workflow of MLN‐TK, able to detect TK rearrangements and to identify unknown TK fusion partners.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory for the Cytogenetic and Molecular Diagnosis of Hematological Malignancies, Centre for Human Genetics, University Hospitals, Leuven, Belgium.
- Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Hôpital Saint-Antoine, Paris, France.
ORCID-Profile: Justine Vanhevel, Barbara Dewaele
Förderung
- Research supported by the Funds Catharina Weekers, Raymond Wuyts, Arlette Lemaître, Yvette Gembauve and Cambier-Sandra, managed by the King Baudouin Foundation
Zitieren
APA
Vanhevel, J., Rack, K., Ameye, G., Mokrani, H., De Bie, J., Michaux, L., & Dewaele, B. (2025). The Use of Optical Genome Mapping for the Detection of Tyrosine Kinase Gene Fusions in Myeloid/Lymphoid Neoplasms. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70640
Vancouver
Vanhevel J, Rack K, Ameye G, Mokrani H, De Bie J, Michaux L, et al. The Use of Optical Genome Mapping for the Detection of Tyrosine Kinase Gene Fusions in Myeloid/Lymphoid Neoplasms. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70640
BibTeX
@article{Vanhevel2025,
author = {Vanhevel, Justine and Rack, Katrina and Ameye, Geneviève and Mokrani, Hayat and De Bie, Jolien and Michaux, Lucienne and Dewaele, Barbara},
title = {The Use of Optical Genome Mapping for the Detection of Tyrosine Kinase Gene Fusions in Myeloid/Lymphoid Neoplasms},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70640}
}
EUVIMED